[November 12, 2014]

SolaranRx's Peptide Selected Among the 2014 Top 10 Most Interesting Oncology Projects to Watch

SolaranRx, Inc. has been chosen by Informa (News - Alert) and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch for its lead compound, SRX-1177, to treat metastatic melanoma.

SolaranRX CEO Les Stewart will present at Informa's Therapeutic Area Partnerships meeting at the Hyatt Regency in Boston on Thursday, November 20 within Track 3 (Oncology). He will discuss SRX-1177, a novel peptide linked to a radioisotope that preferentially attaches to melanocortin-1 (MC1) receptors, which are over-expressed in about 80 percent of melanoma cells. SRX-1177 can be used to identify melanoma patients with MC1 receptors. Those patients can then be injected with therapeutic doses of SRX-117 to deliver targeted radiation, while minimizing the impact on healthy cells. This merger of therapy and diagnostics creates a unique theranostic product for metastatic melanoma.

Products selected among the "Top Most Interesting Oncology Projects to Watch" have met rigorous criteria, including unmet medical need, market potential, diversity of indications, strong science, partnering opportunities, and potential for new opportunities beyond initial indications. These were selected by a panel of independent experts who considered the commercial potential of hundreds of compounds.

"Selected products were screened using a strict set of judging criteria and represent what Informa and Kantar Health consider among the most attractive opportunities the industry has to offer," said Bill Bagwell, general manager, Oncology, Kantar Health. "As an industry leader in oncology strategic research and consulting, it is exciting to give these companies exposure to potential investors, partners and acquirers."

"We are honored our technology was chosen among the Top 10 in oncology by an independent panel," said Stewart. "Current treatments for metastatic melanoma do not work for many patients, have potentially serious and sometime fatal side effects, and are very costly. We believe our technology potentially offers physicians a new treatment option for these patients."

About SolaranRx, Inc.

SolaranRx, Inc. is developing a platform of new therapies and companion imaging agents for the treatment of metastatic melanoma. This merger between therapeutics and diagnostics-often referred to as theranostics-constitutes a new level of personalized medicine for treating metastatic melanoma. SolaranRx seeks to improve treatment and patients' quality of life, giving new options to clinicians and hope to patients.

[ Back To TMCnet.com's Homepage ]